Dan has not joined us here yet but I am RTing this because
1) he know biotech
2) I agree with him on AMGN
1) he know biotech
2) I agree with him on AMGN
November 26, 2024 at 2:29 PM
Dan has not joined us here yet but I am RTing this because
1) he know biotech
2) I agree with him on AMGN
1) he know biotech
2) I agree with him on AMGN
#AMGN #$AMGN
False resistance breakout. False seller zone breakout.
https://tr3n.do/stocks/amgn?utm_source=bluesky
False resistance breakout. False seller zone breakout.
https://tr3n.do/stocks/amgn?utm_source=bluesky
September 24, 2026 at 9:41 PM
#AMGN #$AMGN
False resistance breakout. False seller zone breakout.
https://tr3n.do/stocks/amgn?utm_source=bluesky
False resistance breakout. False seller zone breakout.
https://tr3n.do/stocks/amgn?utm_source=bluesky
She's not alone.. The silence from biotech and pharma CEOs — $AMGN $LLY $REGN $GILD — is (to use a cliché) deafening.
Read the story here:
www.statnews.com/2025/02/11/n...
Read the story here:
www.statnews.com/2025/02/11/n...
As outcry builds over Trump cuts to NIH payments, drugmakers are MIA
Drugmakers — major beneficiaries of NIH-backed university research — have been largely silence on the Trump administration's cuts to agency research payments.
www.statnews.com
February 11, 2025 at 7:49 PM
She's not alone.. The silence from biotech and pharma CEOs — $AMGN $LLY $REGN $GILD — is (to use a cliché) deafening.
Read the story here:
www.statnews.com/2025/02/11/n...
Read the story here:
www.statnews.com/2025/02/11/n...
最近最牛逼的交易，简直神了。纯运气！且听我道来：上周四，21号，我在290元左右做多医药股安进$amgn ，但本周一，25号，我感觉这个仓位有点多余，就平仓了，大概赚了20%，这持仓也就一个交易日。其实收益还行！但没想到，周二安进发布了自己减肥药的试验结果（我原以为12月才发布的），结果不好，amgn在周二暴跌12%，我如果周一没平仓，别说赚20%，我得亏80%！太幸运了！😍然后周二，我在amgn当日低点附近，重新做多，周三开盘就平仓了。这一次持仓不到1天，赚了100%！😍😍😍哈哈哈哈哈哈。。。这交易纯运气，无法复制。哈哈哈哈。
November 29, 2024 at 4:22 AM
最近最牛逼的交易，简直神了。纯运气！且听我道来：上周四，21号，我在290元左右做多医药股安进$amgn ，但本周一，25号，我感觉这个仓位有点多余，就平仓了，大概赚了20%，这持仓也就一个交易日。其实收益还行！但没想到，周二安进发布了自己减肥药的试验结果（我原以为12月才发布的），结果不好，amgn在周二暴跌12%，我如果周一没平仓，别说赚20%，我得亏80%！太幸运了！😍然后周二，我在amgn当日低点附近，重新做多，周三开盘就平仓了。这一次持仓不到1天，赚了100%！😍😍😍哈哈哈哈哈哈。。。这交易纯运气，无法复制。哈哈哈哈。
Obesity: fewer injections to keep the weight off? #$VKTX, #$AMGN, #$LLY and #$NVO
www.merlintrader.com/obesity-main...
www.merlintrader.com/obesity-main...
Obesity: Fewer Injections To Keep The Weight Off? $VKTX, $AMGN, $LLY And $NVO
Obesity maintenance: what 85% and 90% mean in $VKTX data, and how to compare trial design, duration and risks with $AMGN, $LLY and $NVO.
www.merlintrader.com
September 24, 2026 at 2:18 PM
Obesity: fewer injections to keep the weight off? #$VKTX, #$AMGN, #$LLY and #$NVO
www.merlintrader.com/obesity-main...
www.merlintrader.com/obesity-main...
#AMGN #$AMGN
Buyer zone formed. Local minimum confirmed. Upward correction.
https://tr3n.do/stocks/amgn?utm_source=bluesky
Buyer zone formed. Local minimum confirmed. Upward correction.
https://tr3n.do/stocks/amgn?utm_source=bluesky
September 21, 2026 at 9:33 PM
#AMGN #$AMGN
Buyer zone formed. Local minimum confirmed. Upward correction.
https://tr3n.do/stocks/amgn?utm_source=bluesky
Buyer zone formed. Local minimum confirmed. Upward correction.
https://tr3n.do/stocks/amgn?utm_source=bluesky
$CAT weighs on the DJIA, but the Index is up $UNH $AMGN @stockcharts
$KO popping 6%
$NVDA -2%
$KO popping 6%
$NVDA -2%
April 28, 2026 at 1:51 PM
$CAT weighs on the DJIA, but the Index is up $UNH $AMGN @stockcharts
$KO popping 6%
$NVDA -2%
$KO popping 6%
$NVDA -2%
BUY $AMGN (AMGN.O) [PharmaStudy] @ 13:00:00Z
September 22, 2026 at 1:00 PM
BUY $AMGN (AMGN.O) [PharmaStudy] @ 13:00:00Z
$amgn ripping 4.7% premarket, 123,348 shares traded. tapeboard chart is up, scanner is tracking the move. these verticals can fade fast on the open.… https://tapeboard.com/go/bsky/research/AMGN?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=amgn-pm-up-tape&utm_term=research
September 22, 2026 at 1:14 PM
$amgn ripping 4.7% premarket, 123,348 shares traded. tapeboard chart is up, scanner is tracking the move. these verticals can fade fast on the open.… https://tapeboard.com/go/bsky/research/AMGN?utm_source=bluesky&utm_medium=post&utm_campaign=bsky-native&utm_content=amgn-pm-up-tape&utm_term=research
Amgen's Horizon-sourced fusion protein succeeds in late-stage Sjögren's study #$AMGN firstwordpharma.com/story/8078935
September 22, 2026 at 10:28 PM
Amgen's Horizon-sourced fusion protein succeeds in late-stage Sjögren's study #$AMGN firstwordpharma.com/story/8078935
$AMGN -8.2% really weighing on the DJIA
September 8, 2026 at 2:06 PM
$AMGN -8.2% really weighing on the DJIA
2/3 Nilesh KUMAR, Wellington Management: Avere Therapeutics, KRSA, MBX
Evan McCULLOCH, Franklin Templeton (FBDIX): BBIO, ONC, RVMD
Salveen RICHTER, Goldman Sachs: AMGN, BIIB, IMNM, TSHA, VRTX
Davis RISINGER, Leering Partners: LTGO, ORKA, PCVX, SCTX, TRAX...
Evan McCULLOCH, Franklin Templeton (FBDIX): BBIO, ONC, RVMD
Salveen RICHTER, Goldman Sachs: AMGN, BIIB, IMNM, TSHA, VRTX
Davis RISINGER, Leering Partners: LTGO, ORKA, PCVX, SCTX, TRAX...
September 25, 2026 at 8:45 PM
2/3 Nilesh KUMAR, Wellington Management: Avere Therapeutics, KRSA, MBX
Evan McCULLOCH, Franklin Templeton (FBDIX): BBIO, ONC, RVMD
Salveen RICHTER, Goldman Sachs: AMGN, BIIB, IMNM, TSHA, VRTX
Davis RISINGER, Leering Partners: LTGO, ORKA, PCVX, SCTX, TRAX...
Evan McCULLOCH, Franklin Templeton (FBDIX): BBIO, ONC, RVMD
Salveen RICHTER, Goldman Sachs: AMGN, BIIB, IMNM, TSHA, VRTX
Davis RISINGER, Leering Partners: LTGO, ORKA, PCVX, SCTX, TRAX...
The Lp(a)-Lowering Race (blog): rnaitherapeutics.blogspot.com/2025/02/the-...
$NVS $IONS $ARWR $AMGN $SLN $CRSP $VERV
$NVS $IONS $ARWR $AMGN $SLN $CRSP $VERV
The Lp(a)-Lowering Drug Race
Cardiovascular disease (CVD) remains a leading cause of death and morbidity worldwide. According to the WHO , 18 million of the 68 million ...
rnaitherapeutics.blogspot.com
February 7, 2025 at 8:50 AM
The Lp(a)-Lowering Race (blog): rnaitherapeutics.blogspot.com/2025/02/the-...
$NVS $IONS $ARWR $AMGN $SLN $CRSP $VERV
$NVS $IONS $ARWR $AMGN $SLN $CRSP $VERV
#BiotechHangout: Sam Fazeli, Brian Skorney, Matt Gline, Yaron Werber on market & policy: MFN & revenue sharing, IPOs (#$ETRA), Heidi Overton's FDA confirmation hearing, #$CMPX, stock moves: #$OMER, #$CGEM, #$MAZE, data: #$VRTX, #$CLDX, #$VKTX, #$AMGN, #$IONS, #$MRNA, #$ROIV, #$LXEO, Roche: bit.ly/3TjKnby
September 25, 2026 at 2:07 PM
#BiotechHangout: Sam Fazeli, Brian Skorney, Matt Gline, Yaron Werber on market & policy: MFN & revenue sharing, IPOs (#$ETRA), Heidi Overton's FDA confirmation hearing, #$CMPX, stock moves: #$OMER, #$CGEM, #$MAZE, data: #$VRTX, #$CLDX, #$VKTX, #$AMGN, #$IONS, #$MRNA, #$ROIV, #$LXEO, Roche: bit.ly/3TjKnby
Firing Powell is economic melodrama. In biotech, market stability is crucial; fiscal upheavals disrupt R&D and inflate financing costs. Firms like $AMGN depend on steady policies. Check @bluestocks.app for more. #econsky
April 17, 2025 at 9:07 PM
Firing Powell is economic melodrama. In biotech, market stability is crucial; fiscal upheavals disrupt R&D and inflate financing costs. Firms like $AMGN depend on steady policies. Check @bluestocks.app for more. #econsky
in my opinion, there is a phenomenon where financial markets are not reflecting an underlying economic reality, largely centered around A.I. stocks. but the DJIA doesn't even have that much exposure to it when Caterpillar and Goldman Sachs combine to make up 23% of the index value
July 2, 2026 at 9:45 PM
in my opinion, there is a phenomenon where financial markets are not reflecting an underlying economic reality, largely centered around A.I. stocks. but the DJIA doesn't even have that much exposure to it when Caterpillar and Goldman Sachs combine to make up 23% of the index value
On #BiotechHangout, Mike Yee, Bruce Booth, Eric Schmidt & Yaron Werber discuss Jefferies Conference, Atlas Year in Review, investor sentiment, #ACR24 recap $AMGN Ph3 & cell therapy data for SLE, SSC, IMNM & lipid ROs: $LLY, $SLN, $NAMS, $INCY/Escient, Dr. Oz at CMS x.com/biotechch/st... #BioSky $XBI
x.com
x.com
November 22, 2024 at 6:42 PM
On #BiotechHangout, Mike Yee, Bruce Booth, Eric Schmidt & Yaron Werber discuss Jefferies Conference, Atlas Year in Review, investor sentiment, #ACR24 recap $AMGN Ph3 & cell therapy data for SLE, SSC, IMNM & lipid ROs: $LLY, $SLN, $NAMS, $INCY/Escient, Dr. Oz at CMS x.com/biotechch/st... #BioSky $XBI
？:俺のことはamgnムーンと呼べ！
？:ﾋﾄﾔさんさすがっす🥰amgnムーン！！かっこいいっす〜〜🥰🥰
？:俺様は王子様だからな、王子とよべ！
？:はい！ｼｮｳちゃん王子♡
さっすが、ｼｮｳちゃん🥰
↑あのー
？:ﾋﾄﾔさんさすがっす🥰amgnムーン！！かっこいいっす〜〜🥰🥰
？:俺様は王子様だからな、王子とよべ！
？:はい！ｼｮｳちゃん王子♡
さっすが、ｼｮｳちゃん🥰
↑あのー
May 27, 2024 at 4:01 PM
？:俺のことはamgnムーンと呼べ！
？:ﾋﾄﾔさんさすがっす🥰amgnムーン！！かっこいいっす〜〜🥰🥰
？:俺様は王子様だからな、王子とよべ！
？:はい！ｼｮｳちゃん王子♡
さっすが、ｼｮｳちゃん🥰
↑あのー
？:ﾋﾄﾔさんさすがっす🥰amgnムーン！！かっこいいっす〜〜🥰🥰
？:俺様は王子様だからな、王子とよべ！
？:はい！ｼｮｳちゃん王子♡
さっすが、ｼｮｳちゃん🥰
↑あのー
#$AMGN dazodalibep met its Phase 3 goal in moderate-to-severe Sjögren’s disease, showing lasting improvement in systemic activity. A second trial is due later in 2026. notreload.xyz/xy/amgen-dru...
Amgen Drug Succeeds in Phase 3 Sjögren’s Trial
Amgen’s dazodalibep met its Phase 3 goal in moderate-to-severe Sjögren’s disease, showing lasting improvement in systemic activity. A second trial is due later in 2026.
notreload.xyz
September 22, 2026 at 6:55 PM
#$AMGN dazodalibep met its Phase 3 goal in moderate-to-severe Sjögren’s disease, showing lasting improvement in systemic activity. A second trial is due later in 2026. notreload.xyz/xy/amgen-dru...